Preliminary Scientific Program - ICTHIC April 8-10, 2016 Friday April 8 th 2016 9,00-11,00 am Industry sponsored session 11,00-11,15 am Congress Opening: A Falanga, FR Rickles, B Brenner 11,15-1,30 pm Plenary Session 1: Epidemiology of thrombosis in cancer Chairs: N Key (USA); TBA - Venous thromboembolism and occult cancer: impact on clinical practice M Carrier (Canada) - Cancer associated thrombosis: risk factors and outcomes S Eichingher (Austria) - Update of incidental VTE in cancer H Liebman (USA) - Thrombosis and anticancer therapies: the contribution of chemotherapy and the specific drugs implicated in CAT P Mismetti (France)
2,30-4,45 pm Plenary Session 2: Role of hemostatic pathways in cancer progression Chairs: TBA - Microparticles and cancer thrombosis in animal models C Dubois (France) - Inhibition of platelet function as a target for cancer progression control J Italiano (USA) - Biological basis of personalised anticoagulation in cancer: oncomir networks as regulators of coagulopathy J Rak (Canada) - Heparanase procoagulant activity in cancer progression Y Nadir (Israel)
5,15-7,30 pm Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer Chairs: B Brenner (Israel); S Kostantinides (Germany) - Cancer-associated thrombosis novel biomarker discovery N Kuderer (USA) - VTE risk assessment models in cancer I Pabinger (Austria) - Polymorphisms of clotting factors and cancer risk P Sandset (Sweeden) - The HYPERCAN prospective study A Falanga (Italy) 7,30 pm Plenary Lecture: 4th Simon Karpatkin Memorial Lecture Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA) Introduction to Lecture FR Rickles (USA) Targeting clotting proteins in cancer therapy - progress and challenges W Ruf (USA, Germany)
Saturday April 9 th 2016 8,30-10,45 am Plenary Session 4: Hematological malignancies and hemostatic complications Chairs: TBA - Intracranial hemorrhage in cancer patients on anticoagulation J Zwicker (USA) - Management of cancer-associated disseminated intravascular coagulation M Levi (The Netherlands) - New insights into the biology and management of thrombosis in myeloproliferative neoplasms T Barbui (Italy) - Update of thrombosis in multiple myeloma FWG Leebeek (The Netherlands)
11,15 am - 1,30 pm Plenary Session 5: Risk factors for thrombosis in cancer Chairs: I Elalamy (France); GM Liumbruno (Italy) - Upper extremity deep vein thrombosis: comparison between cancer and non-cancer patients SM Bleker (The Netherlands) - Risk of thrombosis and supportive care (transfusion, catheters, growth factors) TBA - New findings from global registries of cancer-associated thrombosis AK Kakkar (UK) - Predictors of recurrent VTE and bleeding on anticoagulation AA Khorana (USA) 2,30-3,00 pm Special Session: History of ICTHIC Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel) History of ICTHIC - How has the field progressed since our first meeting in 2001? F Rickles (USA) 3,00-5,00 pm Poster sessions with refreshments Poster walk discussion sessions with chair
4,30-6,45 pm Plenary Session 6: Prophylaxis of thrombosis in cancer patients Chairs: TBA Thromboprophylaxis in hospitalized Cancer Patients: a comparison of guidelines M. Levine (USA) Long term cardiovascular complications of chemotherapy in patients with cancer P. W. Kamphuisen (The Netherlands) DOACs in cancer patients - what is known and what are the active trials G Agnelli (Italy)
Sunday April 10 th 2016 8,30-10,45 am Plenary Session 7: Treatment of cancer-associated thrombosis Chairs: H ten Cate (The Netherlands); G Lyman (USA) - CAT treatment: guidelines update AYY Lee (Canada) - Management of recurrent venous thromboembolism in cancer patients W Ageno (Italy) - The use of vena cava filter in patients with cancer T Wun (USA) - Management of bleeding complications in cancer patients on DOACs S Schulman (Canada)
11,15 am - 1,30 pm Plenary session 8: Open questions in cancer and thrombosis Chairs: H Buller (Germany) - Anticoagulant and cancer: Will overall survival increase? HH Veersteg (The Netherlands) - Does one size fit all? Who should get LMWH/warfarin/DOACs? S Noble (UK) - LMWH in cancer patients with renal impairment - better than warfarin? R Bauersachs (Germany) - Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients J Harenberg (Germany) 1,30-1,45 pm Concluding Remarks